CCNE1 and ovarian carcinoma: This was further highlighted in the CCNE1-stratified IGNITE trial of recurrent, platinum-resistant ovarian cancer; the ORR was 38% in over-expressed and amplified tumours and 45% in over-expressed only tumours (265).